20/20 BioLabs reports Q2 2026 results; cancer test revenue hits record
20/20 BioLabs (AIDX) reports its second quarter 2026 financial results and notes recent operational progress, stating cancer test revenue reaches a record quarterly level.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.